MEDINET, Yokohama City University, Shin-Yokohama Medical Clinic Jointly Launch Clinical Study of Immune Cell Therapy for Pancreatic Cancer.Tokyo, Japan, Feb 21, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - MEDINET announced on February 20 that it has signed a joint research agreement with Yokohama City University Yokohama City University (横浜市立大学 Yokohama shiritsu daigaku and the Shin-Yokohama Medical Clinic. Accordingly, the three parties have launched a clinical study of immune cell therapy for postoperative adjuvant therapy Adjuvant therapy A treatment done when there is no evidence of residual cancer in order to aid the primary treatment. Adjuvant treatments for endometrial cancer are radiation therapy, chemotherapy, and hormone therapy. in pancreatic cancer pancreatic cancer Malignant tumour of the pancreas. Risk factors include smoking, a diet high in fat, exposure to certain industrial products, and diseases such as diabetes and chronic pancreatitis. Pancreatic cancer is more common in men. . Specifically, they aim to assess the safety and efficacy of combination therapy of gemcitabine and activated autolymphocyte therapy in patients with respectable pancreatic cancer. The joint clinical study will continue through September 2008. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion